Whalesbook
The Introduction of Tishtha: A Biosimilar Breakthrough in Oncology
Zydus Lifesciences has announced the launch of 'Tishtha,' a biosimilar of Nivolumab, in the Indian market, marking a significant step in making advanced cancer treatments more accessible. The drug, designed to treat multiple types of cancer, is positioned as a patient-centric therapy. This launch reinforces Zydus's capabilities in biologics and immuno-oncology, a rapidly growing sector in India.
The introduction of Tishtha follows a crucial Delhi High Court ruling on January 12, 2026, which permitted Zydus to manufacture and market the biosimilar. The court prioritized public interest and patient access to affordable treatment over the patent held by Bristol Myers-Squibb (BMS), the innovator of Nivolumab (marketed as Opdivo/Opdyta). This legal clearance was essential for the drug's market entry.
Enhanced Affordability and Patient Access
A key highlight of Tishtha's launch is its pricing strategy. Available in 100 mg and 40 mg dosages, the drug is priced at Rs 28,950 and Rs 13,950, respectively. These prices are approximately one-fourth of the reference Nivolumab drug, which previously cost between Rs 45,000 to Rs 1 lakh per vial, making it largely unaffordable for many Indian patients. Zydus Lifesciences estimates that this lower cost will benefit over five lakh patients across India, addressing a critical gap in cancer care. The availability of multiple dosage strengths is also intended to help clinicians optimize dosing and minimize drug wastage.
Market Dynamics and Zydus Lifesciences' Position
The Indian biosimilars market, particularly in oncology, is experiencing substantial growth, driven by increasing cancer prevalence and the demand for cost-effective treatments. Nivolumab is a globally significant immuno-oncology drug, and its biosimilar entry is expected to intensify competition and potentially drive down prices for advanced therapies. Zydus Lifesciences, with its focus on innovation and expansion in biologics, is strategically positioned to capitalize on this evolving market landscape. The company has also been actively expanding its regulatory portfolio with USFDA approvals for other products, showcasing its broad operational reach.
Market Performance
Following the announcement of Tishtha's launch and the positive court ruling, Zydus Lifesciences' shares traded higher on January 22, 2026. The stock rose approximately 1.08% to Rs 885.60 on the BSE. This upward movement reflects market sentiment towards the company's strategic expansion into the critical immuno-oncology segment with an affordable offering.
Financial Snapshot
As of January 21-22, 2026, Zydus Lifesciences maintained a market capitalization of approximately ₹87,836 crore. The company's trailing twelve months (TTM) Price-to-Earnings (P/E) ratio was around 17.66x. Recent financial results for Q3 FY25 showed a robust performance, with net profit increasing by 30% year-on-year to ₹1,023.5 crore, supported by a 17% rise in revenue.